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Objectives. To evaluate the analytical performance of an ELISA for the detection of anti-RNA polymerase III antibody (ARA) and to assess
IIF as a method for identifying this antibody.
Methods. A commercially available ELISA was used to assess the presence of ARA in sera from 1018 SSc patients. The sera had been
divided into sub-populations based on the presence of specific autoantibodies, ANA pattern or the absence of both. Patients with ARA
(n¼209) had been identified by characteristic ANA pattern by IIF on HEp-2 cell substrate [and additionally by radio-immunoprecipitation (IP)
in 157/209 cases]. The remaining 809 SSc patients acted as a control group.
Results. Of 157 patients in whom ARA had been confirmed by IP, 150 were positive by ELISA providing a sensitivity of 96%. In the group
where ARA had only been assessed by IIF, 100% (52/52) were ELISA positive. The ANA patterns indicating the presence of ARA were a fine-
speckled nucleoplasmic stain with additional occasional bright dots, with or without concurrent punctate nucleolar staining. In the SSc control
group, the ELISA attained a specificity of 98%, ARA being detected in 17/809 patients.
Conclusions. We report the outcome of a study on a large population of SSc patients that shows the ARA ELISA to be of high analytical
sensitivity and specificity. We confirm that there is minimal overlap between ARA and other SSc-specific autoantibodies. Additionally, it is
demonstrated that the presence of ARA correlates with identifiable patterns by IIF on HEp-2 cell substrate.
KEY WORDS: Anti-ribonucleic acid polymerase antibody, Systemic sclerosis, Anti-nuclear antibody, Indirect immunofluorescence, Enzyme-linked
immunosorbent assay, Autoantibodies.
Introduction
Systemic sclerosis (SSc) is a heterogeneous autoimmune rheumatic
disease characterized by fibrosis of the skin and other organs [1].
SSc patients have autoantibodies to specific cellular components
that are mutually exclusive and correlate with distinct clinical
subsets of disease [2]. The best documented of these, and the only
ones routinely tested outside specialist centres, are ACA and anti-
topoisomerase (anti-Scl-70) (ATA). However, these two specifi-
cities are only positive in  50% of patients with SSc [3]. A third
major subset of SSc patients with distinct clinical features has
antibodies to RNA polymerases (RNAPs). The prevalence of this
antibody is influenced by ethnic origin and varies widely from 4%
to 25% [4–6]. It has been suggested that at least 12% of UK
patients are anti-RNAP antibody (ARA) positive [3]. These
autoantibodies are highly specific and are predominantly present
in patients with dcSSc [2, 7]. They are strongly associated with
hypertensive renal crisis, a serious complication that may be the
presenting feature of disease [8]. Additionally, a number of reports
indicate that the antibody can be demonstrated before the onset of
skin involvement [9–12]. It would therefore be desirable to be able
to detect ARA in the routine clinical laboratory.
Until recently the only specific method for the identification of
ARA was radio-immunoprecipitation (IP), a technique not well
suited to routine use. Using this method the three subtypes of
RNAP (I, II and III) can be precipitated by antibodies and there
are three recognized patterns of reactivity specific for SSc: most
ARA-positive SSc sera precipitate RNAP I and III in combina-
tion, some recognize all three polymerases and a small minority
precipitate RNAP III alone [13]. Some patients with SSc have
antibodies that precipitate only RNAP II, but these do not exhibit
disease specificity [14, 15]. The recent identification of a major
antigenic epitope on RNAP III recognized by almost all sera
positive for ARA by IP [16] has led to the development of an
ELISA for ARA [17]. Unlike IP, ELISA is used in the majority of
diagnostic laboratories making routine detection of ARA feasible.
The technique of IIF is also widely employed for the detection
of autoantibodies. Several studies have noted the association of
ARA with positive staining by IIF on HEp-2 cell substrate.
Interest in SSc-specific ARA by IIF originally focused on a
punctate (speckled) nucleolar pattern consistent with the cellular
location of RNAP I [18]. However, speckled nucleoplasmic
staining patterns were subsequently described, this time consistent
with the cellular location of RNAP III [13, 19]. As a consequence,
there remains no consensus on the specific pattern produced by
SSc-specific ARA on HEp-2 cell substrate.
In this study, we have assessed the utility of two techniques—
IIF on HEp-2 cell substrate and a commercially available
ELISA—to identify patients with ARA. We further evaluated
the specificity of the ELISA method against a large control group
of SSc patients.
Materials and methods
Patient samples
Serum samples were from 1018 SSc patients diagnosed by an
experienced rheumatologist at the Royal Free Hospital, a major
tertiary referral centre for SSc, according to the preliminary ACR
criteria [20]. The local ethics committee gave the study ethical
approval and informed consent was obtained from all patients.
The sera had previously been tested for ANA by IIF on HEp-2
cell substrate (Bion Enterprises Ltd, Des Plaines, IL, USA) and
antibodies to ENAs by counter-immunoelectrophoresis (CIE) or
IP as previously described [3, 21, 22]. Sera were stored at  20
8C
prior to ARA testing by ELISA. Patients were divided into groups
based on autoantibody profile. Two groups were formed of
patients whose sera had produced ANA patterns characteristic of
ARA: ARA-IP (n¼157) (patients in whom the antibody had been
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due to the withdrawal of the radioisotope method from the
laboratory). The remaining 809 sera formed antibody groups as
follows: ACA, n¼197; ATA, n¼210; anti-fibrillarin (U3-RNP)
(AFA), n¼48; anti-Pm-Scl, n¼49; anti-U1-RNP, n¼59; anti-
Ro-60, n¼13; anti-AATS (aminoacyl tRNA synthetases) n¼6;
and anti-Ku, n¼5. In addition, two further groups were formed
from SSc patients with no defined antibody (NDA), n¼174 and
those whose sera produced an ANA pattern of fine-speckled
nucleoplasmic staining with additional homogeneous nucleolar
staining (FSNU), n¼48. The latter group represented a hetero-
geneous population including patients with anti-Th-RNP. As a
consequence of the selection process employed, the antibody
frequencies represented in this study do not reflect the prevalence
of each antibody type in the SSc patient population as a whole.
ARA ELISA
ARA was detected by a commercially available ELISA method
employing a recombinant peptide of RNAP III [6, 16] (Quanta
Lite RNAP III ELISA, INOVA Diagnostics, Inc., San Diego, CA,
USA). The ELISA was performed in accordance with the
manufacturer’s instructions using the recommended cut-off of
20U/ml.
IIF
ANA substrates from five additional manufacturers (HEp2000,
ImmunoConcepts, Sacramento, CA, USA; HEp-2 from Bio-
Diagnostics Ltd, Upton-upon-Severn, UK; Immco Diagnostics,
Buffalo, NY, USA; INOVA Diagnostics Inc.; and The Binding
Site Ltd, Birmingham, UK.) were used to test selected ARA-
positive sera to assess the consistency of the described staining
patterns. IIF was performed as previously described [22].
Statistical analysis
Statistical analysis was performed using SPSS v 11.0 software.
The Mann–Whitney U-test was employed to compare median
levels of ARA in the ARA-IP and ARA-IF groups. The
association between qualitative variables (antibody group and
the presence of ARA by ELISA) was evaluated by Fisher’s exact
test. A P-value of <0.05 was considered to denote statistical
significance in all cases.
Results
Sera from 209 patients with confirmed or suspected ARA were
initially assessed by ELISA. Of the 157 patients in whom ARA
had previously been demonstrated by IP (ARA-IP), 150 sera gave
a positive result by ELISA with a median of 73 U/ml providing a
sensitivity of 96%. An additional 52 patients had previously been
identified by IIF as having one of two staining patterns
characteristic of ARA but had not had the presence of the
antibody confirmed by IP (ARA-IF). ARA was detected by the
ELISA method in sera from all 52 patients and the median ARA
level in these sera was 90.5 U/ml. The staining patterns indicating
the presence of ARA were either a fine-speckled nucleoplasmic
stain with additional occasional bright dots (Fig. 1A), or this same
pattern accompanied by varying intensities of punctate (speckled)
nucleolar staining (Fig. 1B). The fine-speckled nucleoplasmic
pattern typical of anti-Ro and the characteristic patterns of AFA
and anti-Pm-Scl showing clumpy and homogeneous nucleolar
staining respectively are shown for comparison (Fig. 1C–E). In
sera from consecutive ARA-positive SSc patients, 70% produced
the nucleoplasmic only stain and 30% the pattern with additional
punctate nucleolar staining. These two patterns were indistin-
guishable on all six substrate preparations used. There was no
significant difference between the levels of ARA in the ARA-IP
and ARA-IF groups (P¼0.297 by Mann–Whitney U-test) and for
the second part of the study these were considered as one group,
ARA, n¼209. None of the other described antibodies was
demonstrated in any of the 209 sera.
Eight hundred and nine disease control sera (SSc patient sera
characterized for autoantibody and not exhibiting either of the
characteristic staining patterns of ARA) were subsequently tested
for the presence of ARA by ELISA. Out of these, 792 were
negative for ARA, providing a specificity of 98%. The median
level of ARA in each of the control antibody groups was between
5 and 6 U/ml compared with the overall median for the combined
ARA group, 77 U/ml (Fig. 2). Statistically significant negative
associations with the presence of ARA were obtained for the
ACA, ATA, AFA, anti-Pm-Scl, anti-U1-RNP, NDA, and FSNU
groups (P<0.001 by Fisher’s exact test). ARA was detected in
17 of 809 control samples with 10 having only low levels of
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FIG. 2. ARA detected by ELISA in 1018 SSc patients divided into groups based
on autoantibody profile. Boxes show interquartile ranges, lines within the
boxes indicate median values and lines outside the boxes indicate maximum
and minimum values excluding outliers (represented by dots). Numbers in each
group are shown on the figure. The line represents the 20 U/ml cut-off suggested
by the manufacturer.
FIG. 1. ANA patterns by IIF on HEp-2 cell substrate. (A) Fine-speckled
nucleoplasmic stain with additional occasional bright dots: ARA. (B) Fine-speckled
nucleoplasmic stain with additional occasional bright dots accompanied by
punctate (speckled) nucleolar staining: ARA. (C) Fine-speckled nucleoplasmic
stain: anti-Ro. (D) Clumpy nucleolar stain: AFA. (E) Homogenous (very fine
speckled) nucleoplasmic with homogenous nucleolar stain: anti-PmScl.
Detection of anti-RNA polymerase antibody 977reactivity (20–30 U/ml). None of these showed any evidence of the
characteristic ANA patterns associated with ARA. IP results were
available for the single ELISA positives in the anti-AATS and
anti-Ku groups. Neither was positive for ARA by this method.
Discussion
Despite being described in up to 25% of patients with SSc [5] and
having an important role in disease classification and prediction
of organ involvement [2, 7], detection of ARA has been confined
to a small number of specialist centres and time-consuming IP
assays. The lack of consensus for a specific ANA pattern
associated with these antibodies has previously ruled out IIF as
a screening test. The recent development of an ELISA for ARA
has provided a more accessible test for the detection of these
antibodies [6, 17, 23]. In this study, we have assessed both the
analytical performance of an ELISA method and the reliability of
IIF using HEp-2 cell substrate for the detection of ARA in a large
cohort of SSc patients.
Initially, 157 sera that showed characteristic staining patterns
in which ARA had additionally been confirmed by the gold stan-
dard method of IP were tested. The ELISA performed with 96%
sensitivity, which represents a favourable comparison with IP and
is similar to sensitivities of 91% and 100% achieved in other
studies employing ELISA [17, 23].
The literature suggests that ARA do not produce a specific
pattern by IIF on HEp-2 cell substrate [3, 6, 13, 19, 24]; however,
we contend that discrete patterns of fluorescence can be used to
identify this antibody. There was 100% concordance between IIF
and the ELISA method when testing 52 sera with suspected ARA.
This demonstrates that the patterns can be reliably identified by
experienced observers and suggests that recognition should be
within the capability of most laboratory scientists with appro-
priate training.
To confirm that the distinct patterns observed on HEp-2 cell
substrate were not specific to the slides routinely used in our
laboratory we tested ARA-positive sera on substrate cells from six
different manufacturers. Staining was found to be consistent on all
slides tested. The fine-speckled staining produced by ARA is
different to that produced by Ro antibodies and the punctate
nucleolar staining can be readily distinguished from other patterns
of nucleolar fluorescence such as the homogeneous nucleolar
staining seen with anti-PmScl antibodies and the clumpy nucleolar
staining associated with AFA. Recently, two groups have assessed
IIF as a means of detecting ARA, but principally with a focus on
nucleolar patterns of fluorescence [6, 24]. They both concluded
that although present in a subset of patients, nucleolar IIF was not
a sensitive marker for ARA and that it could not be used to screen
for these antibodies. Our results are entirely consistent with these
conclusions and in line with previous findings we estimate
nucleolar fluorescence to be present in only 30% of ARA-positive
sera [6, 19]. It is not the presence of nucleolar staining but that of
the typical fine-speckled nucleoplasmic pattern that is the
distinctive finding on IIF. Consistent with our observation,
Yamasaki et al [24] reported the presence of the nucleoplasmic
pattern in all of their tested ARA-positive patients.
The availability of an ELISA method has made it possible to
quantify ARA for the first time, an advance that may provide
further correlations to clinical manifestations of disease.
Preliminary evidence has suggested that ARA levels may change
over the course of disease [17]. The majority of patients in the
ARA-IP group had long-standing disease whilst those identified
by IIF (and subsequently confirmed by ELISA) were predomi-
nantly newly diagnosed. Although we found no statistically
significant difference in antibody levels for the two ARA-positive
groups, the median titre of ARA in the ARA-IF group was
observed to be higher than that for the ARA-IP group (median
90.5 U/ml vs 73 U/ml). Further work with serial samples is needed
to identify any relationship between ARA titre and both disease
progression and organ involvement.
In the final part of the study, we found the specificity of the
ELISA to be 98% when tested on a rigorous disease control group
of 809 SSc patients not displaying the characteristic IIF patterns
of ARA. This specificity is similar to those quoted in previous
studies but is markedly better than that seen by another group
who used sera from SSc patients as controls and found 10% (7/72)
gave false-positive results by ELISA [17]. Of the 17 samples in the
current study that gave positive results most had low levels of
reactivity. Two with higher ARA levels by ELISA had previously
been tested by IP; both were negative for ARA by this method and
can be considered false positive by ELISA. Without IP results for
the remaining 15 patients we could not rule out the possibility that
they had low levels of ARA.
It is a characteristic feature of SSc that each patient will
typically have only one of a series of hallmark autoantibodies
[2, 7, 19]. It was therefore expected that patients with defined
SSc-specific antibodies would not exhibit overlap with ARA and
vice versa. Indeed, there was a statistically significant negative
association between ARA and all the SSc-specific autoantibodies.
The NDA and FSNU groups in this study were over-represented
with respect to the SSc population as a whole as it was felt that
these were the most likely sera to contain previously undetected
ARA, there being no other defining antibody other than anti-Th-
RNP. None of the sera in the FSNU group and only 2/174 (1%)
in the NDA group were positive for ARA. These results support
the hypothesis that in the absence of the characteristic staining
patterns described, the presence of ARA is highly unlikely.
In conclusion, we report that the ELISA is both highly sensitive
and specific for the detection of ARA and as such is comparable
with IP as a test for this antibody. In addition, we confirm that
there is minimal overlap between ARA and other SSc-specific
autoantibodies. Finally, we suggest that characteristic patterns of
staining by IIF on HEp-2 cell substrate can reliably indicate the
presence of ARA. Together these advances infer that the detection
of clinically important ARA need not be confined to specialist
centres.
Disclosure statement: R.W.B. and T.T.W. are employees of
INOVA Diagnostics Inc. All other authors have declared no
conflicts of interest.
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